County of Santa Clara v. Astra United States, Inc.

428 F. Supp. 2d 1029, 2006 U.S. Dist. LEXIS 15279, 2006 WL 335422
CourtDistrict Court, N.D. California
DecidedFebruary 14, 2006
DocketC 05-03740 WHA
StatusPublished
Cited by6 cases

This text of 428 F. Supp. 2d 1029 (County of Santa Clara v. Astra United States, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
County of Santa Clara v. Astra United States, Inc., 428 F. Supp. 2d 1029, 2006 U.S. Dist. LEXIS 15279, 2006 WL 335422 (N.D. Cal. 2006).

Opinion

ORDER GRANTING MOTION TO DISMISS

ALSUP, District Judge.

INTRODUCTION

In this putative class action, a county government seeks to recover alleged overcharges for medicines sold by pharmaceutical companies to public hospitals in California. The action is brought under Section 17204 of California’s Unfair Competition Law (“UCL”) and under California’s False Claims Act (“CFCA”), among other theories. Having successfully removed the action from state court, defendants now move to dismiss. The grounds for the motion are that plaintiff lacks standing, that plaintiffs state-law claims are preempted by federal law, that primary jurisdiction rests with the Department of Health and Human Services and its Office of Inspector General, that plaintiff has failed to meet the pleading requirements of FRCP 8 and 9(b), and that plaintiff is not the real party in interest. Defendant SmithKline Beecham has filed a supplemental motion to dismiss on grounds that all four of plaintiffs claims are time-barred.

For reasons explained below, this order holds that plaintiff has no standing to bring suit under the “any person” provision of the UCL. The UCL claim, as pled, must be Dismissed. Plaintiffs CFCA claim is Dismissed for failure to meet FRCP 9(b)’s pleading requirements for fraud.

STATEMENT

Defendants are drug manufacturers and distributors. They sell pharmaceuticals to public hospitals and health-care clinics. As required by state law, Santa Clara County pays the cost of drugs for many indigent and other patients at such medical facilities. In 2004, the county spent more than $30 million on prescription and over-the-counter medications for outpatients.

The Public Health Service Act of 1992 established a drug discount program called the Section 340B program. 42 U.S.C. 256b. The 340B program requires pharmaceutical manufacturers to provide a statutorily defined discount on outpatient drugs to qualified entities. Manufacturers are required to participate in the 340B program as a condition of having their drug charges reimbursed by Medicaid. Manufacturers must enter into a Pharmaceutical Pricing Agreement with the Department of Health and Human Services. The 340B program is overseen by the Health Resources and Services Administration (“HRSA”), an agency within the department. Immediate responsibility for oversight of the 340B program resides in HRSA’s Office of Pharmacy Affairs.

This lawsuit was evidently provoked by a series of federal reports raising a concern about overcharges. More specifically, in March 2003, the Office of Inspector General of the Department of Health and Human Services issued a report entitled *1032 “Pharmaceutical Manufacturers Overcharged 340B-Covered Entities.” The report stated that five pharmaceutical manufacturers had overcharged 340B entities during the one-year period ending September 30, 1999. The OIG issued another report in June 2004 entitled “Appropriateness of 340B Drug Prices.” It examined the prices paid by 340B entities in September 2002. It found that 340B entities overpaid and did not receive the correct discount for 31 percent of sampled drug purchases. The report estimated that 340B entities overpaid $41.1 million for the sample month. No specific manufacturers, 340B entities or drug prices were identified in the report. On October 21, 2004, the OIG withdrew the June 2004 report. The OIG stated that it had found problems with the data used to support the finding that the sampled prices exceeded the 340B ceiling price. The OIG expects to release a new report in spring 2006 to determine whether 340B entities paid the appropriate price.

Santa Clara County sued defendants in Alameda County Superior Court, claiming they had overcharged for drugs. Santa Clara asserted four claims on behalf of itself and other similarly situated California counties: violations of Section 17200 of California’s Unfair Competition Law and California’s False Claims Act, for an accounting and for unjust enrichment. Defendants removed the action here claiming diversity and federal-question jurisdiction. Santa Clara’s motion for remand was denied on the basis of federal-question subject-matter jurisdiction.

ANALYSIS

A motion to dismiss under Rule 12(b)(6) tests the legal sufficiency of the claims alleged in the complaint. A complaint should not be dismissed “unless it appears beyond doubt that the plaintiff can prove no set of facts in support of his claim which would entitle him to relief.” Conley v. Gibson, 355 U.S. 41, 45-46, 78 S.Ct. 99, 2 L.Ed.2d 80 (1957). On the other hand, “conclusory allegations of law and unwarranted inferences are insufficient to defeat a motion to dismiss for failure to state a claim.” Epstein v. Wash. Energy Co., 83 F.3d 1136, 1140 (9th Cir.1996). “[T]he Federal Rules of Civil Procedure do not require a claimant to set out in detail the facts upon which he bases his claim. To the contrary, all the Rules require is ‘a short and plain statement of the claim’ that will give the defendant fair notice of what the plaintiffs claim is and the grounds upon which it rests.” Conley, 355 U.S. at 47, 78 S.Ct. 99 (quoting Rule 8(a)(2)). Allegations of fraud, however, must meet the heightened pleading standards of FRCP 9(b). These require allegations of particular facts going to the circumstances of the fraud, including time, place, persons, statements made and an explanation of how or why such statements are false or misleading. In re GlenFed, Inc. Sec. Litig., 42 F.3d 1541, 1547-48 n. 7 (9th Cir.1994) (en banc).

1. The Section 17200 Claim.

California Business and Professions Code Section 17200 prohibits “any unlawful, unfair or fraudulent business act or practice and unfair, deceptive, untrue or misleading advertising.... ” The California Supreme Court has stated that “[t]he Legislature intended this sweeping language to include anything that can properly be called a business practice and that at the same time is forbidden by law.” Stop Youth Addiction, Inc. v. Lucky Stores, Inc., 17 Cal.4th 553, 560, 71 Cal.Rptr.2d 731, 950 P.2d 1086 (1998) (citations omitted). Among others, Section 17204 authorizes “any person who has suffered injury in fact and has lost money or property as a result of ... unfair competition” to sue under Section 17200. Section 17201 defines “person” to “mean and include natu *1033 ral persons, corporations, firms, partnerships, joint stock companies, associations and other organizations of persons.”

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States ex rel. Modglin v. DJO Global Inc.
48 F. Supp. 3d 1362 (C.D. California, 2014)
In Re Cell Tower Litigation
807 F. Supp. 2d 928 (S.D. California, 2011)
In Re Pharmaceutical Industry Average Wholesale Price Litigation
478 F. Supp. 2d 164 (D. Massachusetts, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
428 F. Supp. 2d 1029, 2006 U.S. Dist. LEXIS 15279, 2006 WL 335422, Counsel Stack Legal Research, https://law.counselstack.com/opinion/county-of-santa-clara-v-astra-united-states-inc-cand-2006.